MOLECULAR CHARACTERISATION OF CANINE BREAST CARCINOMA AT THE TISSUE AND PLASMATIC LEVEL (Q3135597): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): WITH PREVIOUS STUDIES ON CANINE BREAST TUMORS (PM98-0164, AGL03-6289, AGL2006-09016, CVI-P07-02559, AGL2011-025553) WE HAVE SHOWN THAT: ESTROGEN RECEPTOR (RE) AND PROGESTERONE (RP) RECEPTOR TUMORS HAVE LOWER RECURRENCE RATES AND LOWER HER-2 EXPRESSION AND RESPOND TO ENDOCRINE TREATMENT WITH A DECREASE IN CELL PROLIFERATION IN VIVO AND IN VITRO; AND II) THAT THE MOST HETEROGENEOUS CELL POPULATION IN TERMS OF MORPHOLOGY AND IMMUNOPHENOTYPE IS THAT...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
MOLECULAR CHARACTERISATION OF CANINE BREAST CARCINOMA AT THE TISSUE AND PLASMATIC LEVEL | |||
Revision as of 12:36, 12 October 2021
Project Q3135597 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MOLECULAR CHARACTERISATION OF CANINE BREAST CARCINOMA AT THE TISSUE AND PLASMATIC LEVEL |
Project Q3135597 in Spain |
Statements
70,760.8 Euro
0 references
88,451.0 Euro
0 references
80.0 percent
0 references
1 January 2016
0 references
11 July 2016
0 references
UNIVERSIDAD DE CORDOBA
0 references
37°53'4.49"N, 4°46'33.64"W
0 references
14021
0 references
CON ESTUDIOS ANTERIORES SOBRE TUMORES DE MAMA CANINOS (PM98-0164, AGL03-6289, AGL2006-09016, CVI-P07-02559, AGL2011-025553) HEMOS DEMOSTRADO QUE: I) LOS TUMORES CON RECEPTORES DE ESTROGENOS (RE) Y RECEPTORES DE PROGESTERONA (RP) PRESENTAN MENOR TASA DE RECIDIVAS Y MENOR EXPRESION DE HER-2 Y QUE RESPONDEN AL TRATAMIENTO ENDOCRINO CON UN DESCENSO DE LA PROLIFERACION CELULAR TANTO IN VIVO COMO IN VITRO; Y II) QUE LA POBLACION CELULAR MAS HETEROGENEA EN CUANTO A MORFOLOGIA E INMUNOFENOTIPO ES LA DE CELULAS MIOEPITELIALES (ME), QUE COMPARTE CON LA POBLACION DE CELULAS BASALES LA EXPRESION DE CITOQUERATINAS DE TIPO BASAL. EN LA ESPECIE HUMANA SE HA DEMOSTRADO LA EXISTENCIA DE VARIOS TIPOS DE CANCER DE MAMA EN FUNCION DE SU FENOTIPO MOLECULAR Y EL TIPO BASAL ES EL DE MAYOR AGRESIVIDAD BIOLOGICA. EN LA ESPECIE CANINA SE HAN DEFINIDO SUBTIPOS EQUIVALENTES UTILIZANDO TECNICAS INMUNOHISTOQUIMICAS Y SE HA SUGERIDO QUE EL NIVEL DE (DES)DIFERENCIACION DE LAS CELULAS ME PODRIA SER EL RESPONSABLE DE SU MAYOR AGRESIVIDAD BIOLOGICA. CON ESTE PROYECTO PRETENDEMOS ANALIZAR EL FENOTIPO MOLECULAR DEL CANCER DE MAMA CANINO MEDIANTE ESTUDIOS DE EXPRESION GENICA TANTO A NIVEL TISULAR COMO PLASMATICO (BIOPSIA LIQUIDA) PARA SU APLICACION EN LA EVALUACION CLINICA PRONOSTICA Y TERAPEUTICA DE LOS ANIMALES CON TUMORES MALIGNOS DE MAMA. (Spanish)
0 references
WITH PREVIOUS STUDIES ON CANINE BREAST TUMORS (PM98-0164, AGL03-6289, AGL2006-09016, CVI-P07-02559, AGL2011-025553) WE HAVE SHOWN THAT: ESTROGEN RECEPTOR (RE) AND PROGESTERONE (RP) RECEPTOR TUMORS HAVE LOWER RECURRENCE RATES AND LOWER HER-2 EXPRESSION AND RESPOND TO ENDOCRINE TREATMENT WITH A DECREASE IN CELL PROLIFERATION IN VIVO AND IN VITRO; AND II) THAT THE MOST HETEROGENEOUS CELL POPULATION IN TERMS OF MORPHOLOGY AND IMMUNOPHENOTYPE IS THAT OF MYOEPITHELIAL CELLS (ME), WHICH SHARES WITH THE POPULATION OF BASAL CELLS THE EXPRESSION OF BASAL-TYPE CYTOKERATINS. SEVERAL TYPES OF BREAST CANCER HAVE BEEN SHOWN TO EXIST IN THE HUMAN SPECIES BASED ON THEIR MOLECULAR PHENOTYPE AND THE BASAL TYPE IS THE MOST BIOLOGICALLY AGGRESSIVE. IN THE CANINE SPECIES EQUIVALENT SUBTYPES HAVE BEEN DEFINED USING INMUNOHISTOQUIMICAS TECHNIQUES AND IT HAS BEEN SUGGESTED THAT THE LEVEL OF (DE)DIFFERENTIATING THE CELLS COULD BE RESPONSIBLE FOR THEIR GREATER BIOLOGICAL AGGRESSIVENESS. WITH THIS PROJECT WE AIM TO ANALYSE THE MOLECULAR PHENOTYPE OF CANINE BREAST CANCER BY MEANS OF GENIC EXPRESSION STUDIES AT BOTH TISSUE AND PLASMATIC LEVEL (LIQUID BIOPSY) FOR ITS APPLICATION IN CLINICAL PROGNOSTIC AND THERAPEUTIC EVALUATION OF ANIMALS WITH MALIGNANT BREAST TUMORS. (English)
12 October 2021
0 references
Córdoba
0 references
Identifiers
AGL2015-64316-R
0 references